Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Collaborator: Immunex Corporation
• Treatments: Dexamethasone; Docetaxel; Etanercept; Glucocorticoids

Criteria

Inclusion Criteria:

• Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists.

• Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option:

• Non-Small Cell Lung

• Breast

• Head and Neck

• Esophageal

• Stomach

• Ovarian carcinomas

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

• Life expectancy of at least 12 weeks.

• Must have adequate organ function

• Peripheral Neuropathy must be less than Grade 2